Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 4/20 | 0.64 |
| ▸ | TYMS | P04818 | 4/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1889086 | 0.89 | DUT (0.66) | DUTTYMSP2RY2P2RY4P2RY6 | |
| SCHEMBL1886250 | 0.85 | P2RY6 (0.60) | P2RY2P2RY4P2RY6 | |
| SCHEMBL1891219 | 0.85 | DUT (0.59) | DUTTYMSP2RY2P2RY4P2RY6 | |
| SCHEMBL1886854 | 0.84 | POLB (0.61) | DUTTYMSP2RY2P2RY4P2RY6 | |
| Deoxyuridine Monophosphate SCHEMBL25024676 | 0.79 | DUT (0.77) | DUTTYMS | |
| Deoxyuridine Monophosphate SCHEMBL8200 | 0.79 | DUT (0.77) | DUTTYMS | |
| Deoxyuridine Monophosphate SCHEMBL21941035 | 0.79 | DUT (0.77) | DUTTYMS | |
| Deoxyuridine Monophosphate SCHEMBL888328 | 0.79 | DUT (0.77) | DUTTYMS | |
| SCHEMBL5051998 | 0.79 | DUT (0.76) | DUTTYMSP2RY2P2RY4P2RY6 | |
| SCHEMBL1889851 | 0.78 | POLB (0.65) | P2RY2P2RY4P2RY6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242087-B2 | Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-08-14 | — | — | US | disclosed |
| US-20110112046-A9 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2011-05-12 | — | — | US | disclosed |
| US-20100093656-A1 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112046-A9 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | MTAP, POLRMT, PNP | DUT 26/4885TYMS 73/4885P2RY2 1009/4885 |
| US-20100093656-A1 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | MTAP, POLRMT, PNP | DUT 26/4885TYMS 73/4885P2RY2 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.